Xref’s Share price increased after Successfully Completing $8 million Placement

On 26 September 2018, Xref Limited (ASX: XF1) announced that it has successfully completed a placement of shares to Australian institutional investors. The company has raised $8 million before costs from institutional investors. After the release of this news the share price increased by 3.226% as on 26 September 2018.

The funds received from the placement will be used for the Company’s expansion which includes strategic integrations and partnerships. These funds will also help to drive the key business metrics of client acquisition, client adoption and annual revenue per account (ARPA). The company is planning to issue 13.3 million fully-paid ordinary shares at price of $0.60 per share. Ord Minnett Limited has managed this placement.

On 3 September 2018, the company announced sales of $1.3 million for July and August of financial year 2018 which represents a new monthly record for the first two months of FY2019. In FY 2018, the reported sales of the company increased by 72% to $7.1 million for FY2018 compared to $4.1 million in the FY2017. Recognized revenue, which reflects usage of Xref credits increased by 63% to $4.8 million in FY2018 from $2.8 million in FY2017. Xref’s software as a service (SaaS) platform has been able to collect 60% more data with five times faster speed than traditional methods. This platform is used by more than 780 direct clients in seven countries which includes 42% of the ASX top 50 companies.  

On 26 September 2018, the company also announced that two of its option holders have exercised a total of 550,000 options at an exercise price of $0.23 into 550,000 fully paid ordinary shares. The company also announced that 148,629 options which were held under Xref’s Employee Option Plan (EOP) have expired after the relevant staff members left the company.

XF1’s share traded at $0.640 with market capitalization of $91.6 million as on 26 September 2018. In the last three months, the stock has moved up stupendously by about 38%.

Dividend Stocks To Buy

Sponsored ad by Kalkine

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here